Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE
暂无分享,去创建一个
M. Unverdorben | T. Vanassche | Cathy Chen | Amparo Santamaria | Paolo Colonna | Christian von Heymann | Manish Saxena | James Jin
[1] J. Douketis,et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. , 2022, Chest.
[2] J. Douketis,et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline Executive Summary. , 2022, Chest.
[3] S. Kahn,et al. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial , 2021, BMJ.
[4] A. Camm,et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[5] P. Colonna,et al. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT‐AF/VTE study , 2020, Clinical cardiology.
[6] J. Douketis,et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. , 2019, JAMA internal medicine.
[7] Hugh Calkins,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.
[8] Hugh Calkins,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.
[9] P. Colonna,et al. Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT‐AF/VTE)—Trial design , 2018, Clinical cardiology.
[10] M. Chung,et al. Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association , 2017, Circulation.
[11] V. Hasselblad,et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. , 2015, The New England journal of medicine.
[12] B. Gersh,et al. Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation , 2015, Circulation.
[13] J. Douketis,et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure , 2014, Thrombosis and Haemostasis.
[14] J. Beyer-Westendorf,et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. , 2014, European heart journal.
[15] Bridge Study Investigators. Bridging anticoagulation: is it needed when warfarin is interrupted around the time of a surgery or procedure? , 2012, Circulation.
[16] D Bergqvist,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.
[17] Arthur L. Allen,et al. A Call to Reduce the Use of Bridging Anticoagulation. , 2016, Circulation. Cardiovascular quality and outcomes.